Problems viewing this newsletter? View it in your browser >

July 10, 2013

Dear Advocate,

We are pleased to announce the release of the new issue of Px Wire, AVAC's quarterly newsletter on HIV prevention research and implementation.

Download the issue and graphics here.

This quarter, Px Wire highlights three recent developments in the field and key issues for each: the World Health Organization (WHO) prequalification of PrePex, a nonsurgical voluntary medical male circumcision device; the positive result from the study of daily oral tenofovir as PrEP for HIV prevention in people who inject drugs; and new WHO guidelines on the use of ARVs, which recommend antiretroviral treatment for all HIV-positive people with CD4 cell counts of 500 or below.

This issue's centerspread features data compiled by the HIV Vaccines & Microbicides Resource Tracking Working Group (RTWG), led by AVAC. The infographics show both the distribution of HIV prevention research & development funding and where research trial participants are located. For more on funding and investment in HIV prevention R&D download the full report, launched earlier this month, at

As always, we welcome your questions and comments at


Forward This IssueDo you know someone who might be interested in receiving this newsletter?
Forward > 

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
Unsubscribe > 

Contact Us T: +1 212 796 6423